Table 3.
Antibody response and titre among patients with cancer and controls.
| A) RBD-IgG antibodies after first dose | |||||
|---|---|---|---|---|---|
| Patients with cancer (N = 71) | Controls (N = 348) | p-value | |||
| RBD-IgG positive N (%) | 23 | (32.4) | 208 | (59.8) | <0.0001 |
| RBD-IgG titre (95%CI) | 0.68 | (0.52–0.89) | 1.22 | (1.02–1.46) | <0.0001 |
| B) RBD-IgG and neutralising antibodies after the second dose | |||||
|---|---|---|---|---|---|
| Patients with cancer (N = 113) | Controls (N = 261) | p-value | |||
| RBD-IgG positive N (%) | 95 | (84.1) | 258 | (98.9) | <0.0001 |
| RBD-IgG titre (95%CI) | 3.25 | (2.7–3.9) | 6.1 | (5.8–6.4) | <0.0001 |
| Neutralising Ab titre (95%CI) | 221.1 | (160.0–305.7) | 482.8 | (410.8–567.5) | <0.0001 |
IgG, immunoglobin G; RBD, receptor-binding domain; CI, confidence interval; IgG, immunoglobin G; RBD, receptor-binding domain; Ab, antibody.